<DOC>
	<DOCNO>NCT01296152</DOCNO>
	<brief_summary>This study do look level Depo-Provera , injectable birth control , blood see whether affected anti-HIV drug Kaletra ( lopinavir/ritonavir [ LPV/r ] ) . It know whether take Depo-Provera together Kaletra change amount Kaletra blood . Therefore , study also look level HIV Kaletra receive shot Depo-Provera . This study evaluate safety Depo-Provera Kaletra use together . In addition state , study also explore effect Depo-Provera immune system .</brief_summary>
	<brief_title>Pharmacokinetic Interactions Between DMPA LPV/r Among HIV-Infected Women</brief_title>
	<detailed_description>The primary study objective address calculate Area Under Concentration-Time Curve ( AUC ) week 0 ( prior DMPA injection ) week 12 ( twelve week DMPA injection ) study participant . DMPA supply administered part protocol , however Kaletra . It require participant already Kaletra base regimen prior enter study , describe eligibility criterion . Arm A AIDS Clinical Trial Group ( ACTG ) A5093 , consist 14 participant administer DMPA without Kaletra , use reference data .</detailed_description>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>HIV1 infection Documentation plasma HIV1 RNA &lt; /= 400 copies/mL within 30 day prior study entry . Last menstrual period &lt; /= 35 day prior study entry . If last menstrual period &gt; 35 day prior study entry , serum folliclestimulating hormone ( FSH ) must &lt; /= 40 MilliInternational unit per Milliliter ( MIU/mL ) Stable antiretroviral ( ARV ) regimen consist BID LPV/r plus 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) least 30 day postpartum least previous 14 day previously stable antiretroviral regimen without modification prior study entry Cluster Differentiation 4 ( CD4+ ) cell count â‰¥200 cells/mm^3 within 30 day prior study entry Certain laboratory value within 30 day prior study entry Premenopausal females normal ovarian function Negative serum urineHuman Chorionic Gonadotropin ( HCG ) pregnancy test within 72 hour prior study entry All subject must agree participate conception process ( e.g. , active attempt become pregnant vitro fertilization ) duration study.Subjects reproductive potential , participate sexual activity could lead pregnancy , must agree use additional reliable method contraception study . Ability willingness give write informed consent Documentation Pap smear within one year prior study entry . Documentation hepatitis B ( surface antigen ) hepatitis B ( core antibody ) hepatitis C ( antibody ) status prior study entry . Documentation varicellazoster virus ( VZV ) status history varicella herpes zoster , history varicella herpes zoster vaccination documentation antiVZV antibody . Willingness abstain alcohol 24 hour prior 10hour pharmacokinetic ( PK ) specimen draw . Willingness abstain grapefruit product supplement 24 hour prior entry duration study . Received DMPA within 180 day prior study entry . Received hormonal therapy within 30 day prior study entry . Concurrent dual nucleoside therapy zidovudine ( ZDV ) stavudine ( d4T ) within 30 day prior study entry . Use prohibit medication within 30 day prior study entry . Prohibited Medications : amiodarone ( Cordarone ) astemizole ( Hismanal ) bepridil ( Vascor ) carbamazepine ( Tegretol ) cisapride ( Propulsid ) clarithromycin ( Biaxin ) cyclosporine ( Sandimmune , Neoral ) dihydroergotamine ( Migranal others ) ergotamine ( Ergostat , Gotamine , others ) erythromycin ( Emycin , erythromycin ethylsuccinate ( EES ) others ) flecainide ( Tambocor ) glucocorticoid Hypericum perforatum ( St. John 's wort ) itraconazole ( Sporanox ) ketoconazole ( Nizoral ) lovastatin ( Mevacor ) midazolam ( Versed ) nefazadone ( Serzone ) phenobarbital ( Luminal ) phenytoin ( Dilantin ) pimozide ( Orap ) pioglitazone ( Actos ) propafenone ( Rythmol ) propofol ( Diprivan ) quinidine ( Quinidex ) rifabutin ( Mycobutin ) rifampin ( Rifadin , Rifamate , Rifater , Rimactane ) rosiglitazone ( Avandia ) simvastatin ( Zocor ) tacrolimus ( Prograf ) terfenadine ticlopidine ( Ticlid ) , triazolam ( Halcion ) Breastfeeding . Less 30 day postpartum study entry . Bilateral oophorectomy . Hypersensitivity DMPA , MPA , ingredient DMPA . More 50 % change tobacco smoking within 30 day prior study entry plan significantly change tobacco use study . Invasive cancer reproductive tract ; know suspected malignancy breast , know increase risk breast cancer ; undiagnosed vaginal bleeding ; liver tumor ; serious ocular disorder time prior study entry . Uncontrolled hypothyroidism hyperthyroidism within 30 day study entry . Acute infection opportunistic disease require medication within 14 day prior study entry . Receipt immunization within 2 week prior enrollment . Use immunosuppressant medication include systemic corticosteroid within 30 day prior study entry . Chronic immunosuppressive condition HIV . Initiated , discontinue , change dos drug cytochrome P450 3A4 ( CYP3A4 ) substrates within 30 day study entry . History deep venous thrombosis pulmonary embolus .</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>